Genetic testing has a critical role in patients’ care as genetic information helps physicians to distinguish between types of neuromuscular disorders, informs prognosis and treatment decisions, and determines patients’ eligibility for new and emerging therapies.

Selecting the right genetic test and incorporating genetic information to reach a diagnosis and formulate a treatment plan require deep familiarity and can be challenging for many clinicians. To bridge these gaps, MDA, together with key opinion leaders in the field, created a webinar that answers many questions regarding genetic testing and its impact.

Laurie Gutmann, MD, from the University of Iowa, and Shawna Feely, MS, CGC, from Iowa’s Carver College of Medicine, created a detailed presentation for an MDA-produced webinar that fully covers the genetic diagnosis procedure in patients with neuromuscular disease. During this webinar, Dr. Gutmann and Shawna discuss the relevance and practical considerations of genetic testing, as well as the integration of genetic testing into a treatment plan.

For more details, visit https://webinars.on24.com/MDA/Genetic_Testing.

This program is supported in part by an educational grant from Sanofi Genzyme.